EMS subsidiary Brace Pharma Capital returned to help HPV therapy developer Antiva Biosciences increase its overall funding to $57m.
Antiva Biosciences, a US-based human papilloma virus (HPV) therapy developer, raised $15m yesterday in a series C1 round featuring Brace Pharma Capital, the investment arm of pharmaceutical firm EMS.
Hillhouse Capital Management led the round, while spinout-focused investment firm Osage University Partners, Sirona Capital, Canaan Partners, Sofinnova Ventures and Lumira Capital also took part.
Founded in 2012, Antiva is developing topical therapeutics for conditions caused by HPV infection. Its lead candidate, ABI-1968, is currently undergoing two phase 1b clinical studies…